A thiadiazolidine in which the 1,3-thiazolidine ring is substituted by two oxo groups.
ChEBI ID: 50990
Member | Definition | Role |
---|---|---|
2-[2,4-dioxo-3-(phenylmethyl)-5-thiazolidinyl]acetic acid | 2-[2,4-dioxo-3-(phenylmethyl)-5-thiazolidinyl]acetic acid | |
as 605240 | A quinoxaline derivative that is quinoxaline in which the hydrogen at position 6 is replaced by a (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl group. It is a potent inhibitor of the PI3Kgamma, with an IC50 of 8 nM and inhibits the progression of joint inflammation and damage in both lymphocyte-independent and dependent mouse models of rheumatoid arthritis. | (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione |
hydroxypioglitazone | A member of the class of thiazolidenediones that is the hydroxy derivative of pioglitazone. | hydroxypioglitazone |
pioglitazone | A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity. | pioglitazone |
rosiglitazone | rosiglitazone |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (0.01) | 18.7374 |
1990's | 228 (2.76) | 18.2507 |
2000's | 3,543 (42.87) | 29.6817 |
2010's | 3,769 (45.61) | 24.3611 |
2020's | 723 (8.75) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 1,381 (15.03%) | 5.53% |
Reviews | 862 (9.38%) | 6.00% |
Case Studies | 199 (2.17%) | 4.05% |
Observational | 26 (0.28%) | 0.25% |
Other | 6,719 (73.14%) | 84.16% |